Down-regulated progesterone receptor A and B coinciding with successful treatment of endometrial hyperplasia by the levonorgestrel impregnated intrauterine system

Acta Obstetricia et Gynecologica Scandinavica

Volumn 89, Issue 11, 2010, Pages 1438-1446

  Ørbo, Anne ^a,b   Arnes, Marit ^a   Pettersen, Inger ^b   Larsen, Kurt ^b   Hanssen, Karin ^b   Moe, Bjorn ^b  

^a UNIVERSITY OF TROMSØ   (Norway)

^b UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

Author keywords

Endometrial hyperplasia; LNG IUS; PG R; Therapy response; Uterus

Indexed keywords

CASPASE 3; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; METALLOTHIONEIN; PROGESTERONE RECEPTOR A; PROGESTERONE RECEPTOR B; PROTEIN BAX; PROTEIN BCL 2;

ADULT; AGED; APOPTOSIS; ARTICLE; DRUG SAFETY; ENDOMETRIUM HYPERPLASIA; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; INTRAUTERINE CONTRACEPTIVE DEVICE; MAJOR CLINICAL STUDY; NORWAY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 77958453918     PISSN: 00016349     EISSN: 16000412     Source Type: Journal    
DOI: 10.3109/00016349.2010.512068     Document Type: Article

References (30)

1. Horn LC, Schnurrbusch U, Bilek K, Hentschel B, Einenkel J. Risk of progression in complex and atypical endometrial hyperplasia: clinicopathologic analysis in cases with and without progestogen treatment. Int J Gynecol Cancer. 2004;14: 348-353
2. Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients. Cancer. 1985;56:403-412
3. Ferenczy A, Gelfand M. The biologic significance of cytologic atypia in progestogen-treated endometrial hyperplasia. Am J Obstet Gynecol. 1989;160:126-131
4. Randall TC, Kurman RJ. Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40. Obstet Gynecol. 1997;90: 434-440
5. Lindahl B, Alm P, Ferno M, Norgren A. Endometrial hyperplasia: a prospective randomized study of histopathology, tissue steroid receptors and plasma steroids after abrasio, with or without high dose gestagen treatment. Anticancer Res. 1990;10:725-730
6. Vereide AB, Arnes M, Straume B, Maltau JM, Orbo A. Nuclear morphometric changes and therapy monitoring in patients with endometrial hyperplasia: a study comparing effects of intrauterine levonorgestrel and systemic medroxyprogesterone. Gynecol Oncol. 2003;91:526-533
7. Clarke CL, Sutherland RL. Progestin regulation of cellular proliferation. Endocr Rev. 1990;11:266-301.
8. Vereide AB, Kaino T, Sager G, Arnes M, Orbo A. Effect of levonorgestrel IUD and oral medroxyprogesterone acetate on glandular and stromal progesterone receptors (PRA and PRB), and estrogen receptors (ER-alpha and ER-beta) in human endometrial hyperplasia. Gynecol Oncol. 2006;101:214-223
9. Vereide AB, Kaino T, Sager G, Orbo A. Bcl-2, BAX, and apoptosis in endometrial hyperplasia after high dose gestagen therapy: a comparison of responses in patients treated with intrauterine levonorgestrel and systemic medroxyprogesterone. Gynecol Oncol. 2005;97:740-750
10. Baak JP, Nauta JJ, Wisse-Brekelmans EC, Bezemer PD. Architectural and nuclear morphometrical features together are more important prognosticators in endometrial hyperplasias than nuclear morphometrical features alone. J Pathol. 1988;154:335-341
11. Orbo A, Baak JP, Kleivan I, Lysne S, Prytz PS, Broeckaert MA, et al. Computerised morphometrical analysis in endometrial hyperplasia for the prediction of cancer development. A long-term retrospective study from northern Norway. J Clin Pathol. 2000;53:697-703.
12. Baak JP, Mutter GL, Robboy S, van Diest PJ, Uyterlinde AM, Orbo A, et al. The molecular genetics and morphometrybased endometrial intraepithelial neoplasia classification system predicts disease progression in endometrial hyperplasia more accurately than the 1994 World Health Organization classification system. Cancer. 2005;103:2304-2312
13. Orbo A, Arnes M, Hancke C, Vereide AB, Pettersen I, Larsen K. Treatment results of endometrial hyperplasia after prospective D-score classification A follow-up study comparing effect of LNG-IUD and oral progestins versus observation only. Gynecol Oncol. 2008;111:68-73.
14. Orbo A, Baak JP. Computer-based morphometric image analysis of endometrial hyperplasia. Tidsskr Nor Laegeforen. 2000;120:496-499
15. Huang A, Pettigrew NM, Watson PH. Immunohistochemical assay for oestrogen receptors in paraffin wax sections of breast carcinoma using a new monoclonal antibody. J Pathol. 1996; 180:223-227
16. Scarselli G, Tantini C, Colafranceschi M, Taddei GL, Bargelli G, Venturini N, et al. Levo-norgestrel-nova-T and precancerous lesions of the endometrium. Eur J Gynaecol Oncol. 1988;9:284-286
17. Nilsson CG, Haukkamaa M, Vierola H, Luukkainen T. Tissue concentrations of levonorgestrel in women using a levonorgestrel-releasing IUD. Clin Endocrinol (Oxf). 1982; 17:529-536 (Pubitemid 12006959)
18. Varma R, Soneja H, Bhatia K, Ganesan R, Rollason T, Clark TJ, et al. The effectiveness of a levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of endometrial hyperplasia-A long-term follow-up study. Eur J Obstet Gynecol Reprod Biol. 2008;139:169-175
19. Perino A, Quartararo P, Catinella E, Genova G, Cittadini E. Treatment of endometrial hyperplasia with levonorgestrel releasing intrauterine devices. Acta Eur Fertil. 1987;18: 137-140
20. Thomas P, Tubbs C, Garry VF. Progestin functions in vertebrate gametes mediated by membrane progestin receptors (mPRs): identification of mPRalpha on human sperm and its association with sperm motility. Steroids. 2009;74: 614-621
21. Gellersen B, Fernandes MS, Brosens JJ. Non-genomic progesterone actions in female reproduction. Hum Reprod Update. 2009;15:119-138
22. Nutu M, Weijdegard B, Thomas P, Bergh C, Thurin- Kjellberg A, Pang Y, et al. Membrane progesterone receptor gamma: tissue distribution and expression in ciliated cells in the fallopian tube. Mol Reprod Dev. 2007;74: 843-850
23. Moe BT, Vereide AB, Orbo A, Jaeger R, Sager G. Levonorgestrel, medroxyprogesterone and progesterone cause a concentration-dependent reduction in endometrial cancer (Ishikawa) cell density, and high concentrations of progesterone and mifepristone act in synergy. Anticancer Res. 2009;29: 1047-1052
24. Orbo A, Moe BT, Gronaas H, Paulssen RH. Early effects of high concentrations of progesterone and mifepristone A gene expression study of endometrial cancer cells (Ishikawa). J Steroid Biochem Mol Biol. 2009;113:139-149
25. Kampa M, Castanas E. Membrane steroid receptor signaling in normal and neoplastic cells. Mol Cell Endocrinol. 2006; 246:76-82.
26. Amezcua CA, Zheng W, Muderspach LI, Felix JC. Down-regulation of bcl-2 is a potential marker of the efficacy of progestin therapy in the treatment of endometrial hyperplasia. Gynecol Oncol. 1999;73:126-136
27. Maruo T, Laoag-Fernandez JB, Pakarinen P, Murakoshi H, Spitz IM, Johansson E. Effects of the levonorgestrel-releasing intrauterine system on proliferation and apoptosis in the endometrium. Hum Reprod. 2001;16:2103-2108
28. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell. 1993;74:609-619
29. Wang H, Critchley HO, Kelly RW, Shen D, BairdDT. Progesterone receptor subtype B is differentially regulated in human endometrial stroma. Mol Hum Reprod. 1998;4:407-412
30. Wang S, Pudney J, Song J, Mor G, Schwartz PE, Zheng W. Mechanisms involved in the evolution of progestin resistance in human endometrial hyperplasia - precursor of endometrial cancer. Gynecol Oncol. 2003;88:108-117